Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWiw5qCUOTByMDFOwI0> MVeyOEBpyqB? MmTYbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Mk[zNlYxQDh5MUG=
POLK WT M{C2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf6TWM2OD1zMT635qCKyrIkgJmxMlfDqM7:TR?= NUHwS2hDOjZyM{G0NFA>
POLK KO NH[zV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\mTWM2OD12LkCz5qCKyrIkgJmxMlkzyqEQvF2= NWDRUIdXOjZyM{G0NFA>
POLK CD M1myO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nJemlEPTB;NT61PgKBkcLz4pEJNU4xOMLizszN NWrtcos1OjZyM{G0NFA>
RLE/Abca3 MVTGeY5kfGmxbjDBd5NigQ>? MnLwNE41yqEQvF2= MonLNVQ1yqCq NF7kOYZqdmS3Y3XzJIEhdW:{cHjvcI9ocWOjbDDjbIFv\2ViZoLvcUBmeGm2aHXsbYFtNWyra3WgcY9zeGixbH;nfUB1dyCjIIfp[IUtKHOycnXh[E1wfXRibX;ydIhwdG:pedMg NFLDfmUzPTd4MEWzPC=>
PMCs M4q3ZWZ2dmO2aX;uJGF{e2G7 M3LxWlAvOeLCk{NCpO69\y:vbB?= MViyOOKhcA>? NHvuXWRk[XW|ZYOgZUBld3OnLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGVicILveIVqdiCuZY\lcEBw\iClb3zsZYdmdi2LwrC= MWiyOVU6PTZ2Mh?=
PMCs NGnxSIVHfW6ldHnvckBCe3OjeR?= MofzNE4zyqEQvHevcYw> MmTFNlTjiJN5MtMgbC=> M3PKNYlv\HWlZYOgbY5kemWjc3XzJIlvKH[rbXXueIlvKGGwZDFOtU1UVUFicILveIVqdg>? MWqyOVU6PTZ2Mh?=
PMCs MlfxSpVv[3Srb36gRZN{[Xl? NWjjenhIOC5{wrFOwIcwdWx? MWW3NkBp MlLPbY5lfWOnczDk[YNz\WG|ZYOgbY4h[3m2b3vldoF1cW5vODDhcoQhTS2lYXTo[ZJqdiCycn;0[Ylv MWKyOVU6PTZ2Mh?=
PMCs M3nJXGZ2dmO2aX;uJGF{e2G7 MXWwMlLDqM7:Zz;tcC=> NIX3SYcyOi9{ND:0PEBp NVGxOHJwcW6lcnXhd4V{KGOnbHygcYloemG2aX;u M{DmcVI2PTl3NkSy
IMR-32 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q4R|cvPeLKkkGyNEDDvWdxbXy= M4rsOFEz6ojUNEigbC=> MkDNTWM2OD14MDFCuYcwdWxiYYSgeIhmKGWwZDDv[kAzPCCqcoOgc4YhcW6ldXLheIlwdg>? MkCxNlU2OzZ|NEW=
HT1080 NH;CZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XCPVEh|ryP MV[yOEBpyqB? M1;1TIxm[WS|IITvJIEhTzJxTTDk[YxigQ>? MnfXNlU2OTh7NkG=
HT1080 NX7xfod[TnWwY4Tpc44hSXO|YYm= MU[xJO69VQ>? NYPlc4czOjRiaNMg NHK3doVqdmS3Y3XzJIEheG:2ZX70JIdtd2KjbDDEUmEh\GGvYXflJJJme3CxboPl MofGNlU2OTh7NkG=
HDFn NXfCVG9iS3m2b4TvfIlkcXS7IFHzd4F6 NEDDSpg4OiCq M33BWWlEPTB;OT6zNUXDqA>? MY[yOVI4Pjd7Mh?=
THP-1 NILhRoJEgXSxdH;4bYNqfHliQYPzZZk> MnHuO|IhcA>? NIGycmVKSzVyPUSuO|cm MW[yOVI4Pjd7Mh?=
HT-29 M3v6UWN6fG:2b4jpZ4l1gSCDc4PhfS=> M{H6eVczKGh? MXHJR|UxRTFzLkS5KS=> MWqyOVI4Pjd7Mh?=
HCT116  MmfOR5l1d3SxeHnjbZR6KEG|c3H5 MVm3NkBp NF3PSnBKSzVyPUGxMlM1LQ>? MlTUNlUzPzZ5OUK=
A431 Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnRRXA2OC1{MECgTXU> M1LQclQ56oDLaB?= M{Kx[YlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NHTmfVgzPTFyMUK5PS=>
T24 MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr3OVAuOjByIFnV NGTwR2w1QOLCiXi= NYrzfIhrcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NILWdY0zPTFyMUK5PS=>
AY-27  MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2CyT|UxNTJyMDDJWS=> MoXoOFjjiImq Ml7jbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MXqyOVExOTJ7OR?=
A549 NFrMXHJHfW6ldHnvckBCe3OjeR?= NUjaRnlZOSEEtXevcWzDqA>? MYOwMVQ5KGh? MVfpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3dCpG9RVsLibWLORS=> MmrLNlQ6PjN4M{W=
MLE12 M2fpSWZ2dmO2aX;uJGF{e2G7 M2fjb|EhyrWpL33MxsA> NEP5Z28xNTR6IHi= NGnk[YpqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4bDqE:STtMgcXJPSQ>? Ml;QNlQ6PjN4M{W=
Jurkat MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWKyNQKBkc7:bR?= NWGxSWxROjUkgJnoxsA> MmTmZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> M3HsXVI1QTF4OEmz
HeLa  NWTqVWF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPZTWM2OD1zMD6yxsDPxE1? NYHXeGJ1OjR5M{KzPVc>
C18-4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTtXXVsOC1zMECg{txO MVvpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NGLw[FEzPDV5MUm4Ni=>
BMG-1  NEP3W3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjBOFAwQDEEoN88[{9u NFrnSVQ{yqCq M2X6eIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M13sV|I{QTB4N{K2
A459 M4CxbGFxd3C2b4Ppd{BCe3OjeR?= Mn\lNVAhdVV? MV[0PEBp NW\GcpNkcW6mdXPld{BieG:ydH;zbZM> MXOyN|kxOjd4Nh?=
MOCK MYTBdI9xfG:|aYOgRZN{[Xl? MXOxNEBuXQ>? M{Ls[lQ5KGh? MUTpcoR2[2W|IHHwc5B1d3Orcx?= M3;SOlI{QTB{N{[2
MMP1 NEXHdFRCeG:ydH;zbZMhSXO|YYm= NVrlXVJ3OTBibWW= M3n1cVQ5KGh? NIX3elFqdmS3Y3XzJIFxd3C2b4Ppdy=> MUWyN|kxOjd4Nh?=
A549 Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[z[HdUOjByIN88US=> MV[yOEBpyqB? NY\RWoJL\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NVG0WI1VOjN6MEW3PVM>
HCT-116 MoLGRZBweHSxc3nzJGF{e2G7 MoH0N{84NjVxMUWg{txoN22u NEKzd2E1QCCq NXHZcWNOemWmdXPld{B1cGVibHX2[Ywhd2ZiQlzIJIF1KGirZ3igZ49v[2WwdILheIlwdg>? MUCyN|cxQDZ4OB?=
HeLa MlPlRZBweHSxc3nzJGF{e2G7 MYCzM|cvPS9zNTFOwIcwdWx? MlTGOFghcA>? MojxdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> NGfBcGEzOzdyOE[2PC=>
HCT116 NGjMeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWwMVExOCEQvHevcYw> NEHafWU1QCCq MnrmbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NHfrXpQzOzVzOEKwNS=>
NCM460 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYWwMVExOCEQvHevcYw> NEL3[HQ1QCCq NFzabndqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M4LWe|I{PTF6MkCx
NT2  M3m4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYOyWJMyOjRiaNMg MV\MSFUxRTRyMPMAjeK2\y:vbB?= M3jiclI{Ozh4NEKw
NT2  NYO2XWZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq2OFghcA>? Moj1UGQ2OD1zMECgxtVoN22u M2CzdFI{Ozh4NEKw
NT2  NXr4Vo8yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHCNVZHPzJiaB?= NWLVdVJuVER3ME2yNQKBkcL3Zz;tcC=> M3f5NFI{Ozh4NEKw
NT2  NYHVcpp4SXCxcITvd4l{KEG|c3H5 MonXOFAx6oDLwsXnM41t NFTvfowzPCCqwrC= MmDSbY5lfWOnczDzbYdvcW[rY3HueEBqdmO{ZXHz[ZMhcW5iY3HzdIF{\S1|LEisPUBi[3Srdnn0feKh MVWyN|M5PjR{MB?=
NTera-2 NGDMNlJHfW6ldHnvckBCe3OjeR?= MYWxNlAh|rypL33s MnzjO|IhcA>? M2XOXJNq\26rZnnjZY51dHliaX7jdoVie2W|IEitbZNweHKxc4ThcoUhdGW4ZXzz MnS4NlI5OjV|NUW=
NCCIT NFzNeHdHfW6ldHnvckBCe3OjeR?= NYjtO5NyOTJyIN88[{9udA>? NYrhRlhMPzJiaB?= MnHVd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiOD3pd49xem:|dHHu[UBt\X[nbIO= M{PzNlIzQDJ3M{W1
NTera-2 NFnXNVlHfW6ldHnvckBCe3OjeR?= M3PZeVEzOCEQvHevcYw> M1;We|czKGh? M4eyXJNq\26rZnnjZY51dHliaX7jdoVie2W|IGTCRXJUKGyndnXsdy=> MonvNlI5OjV|NUW=
NCCIT MUHGeY5kfGmxbjDBd5NigQ>? MVyxNlAh|rypL33s NIHsTGQ4OiCq NFTwWHl{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDURmFTWyCuZY\lcJM> NHvISIszOjh{NUO1OS=>
NCCIT MkD6SpVv[3Srb36gRZN{[Xl? M4HQTFEzOCEQvHevcYw> M2fYUlczKGh? M4H0fpNq\26rZnnjZY51dHliZHXjdoVie2W|IFfTTEBt\X[nbIO= NF;2ZY8zOjh{NUO1OS=>
NTera-2 MXfGeY5kfGmxbjDBd5NigQ>? M1XaOlEzOCEQvHevcYw> Mn63O|IhcA>? NGXqS4R{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDQdo91\WmwIHPhdoJwdnmuIHzleoVtew>? NULtN|VpOjJ6MkWzOVU>
NCCIT M4\oTmZ2dmO2aX;uJGF{e2G7 NIH2dWsyOjBizsznM41t MlHnO|IhcA>? MXTzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCScn;0[YlvKGOjcnLvcpltKGyndnXsdy=> MYqyNlgzPTN3NR?=
NTera-2 MkPBSpVv[3Srb36gRZN{[Xl? M3m2VVEzOCEQvHevcYw> NHXseW84OiCq MlSyd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiTGDPJIxmfmWucx?= M3\VR|IzQDJ3M{W1
NCCIT MYTGeY5kfGmxbjDBd5NigQ>? MWmxNlAh|rypL33s NFS1dVA4OiCq NID3NWN{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz MoLQNlI5OjV|NUW=
MDA-MB-468 M{nkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfNNQKBmzJyMNMg{txoN22O Ml\RNlQhcA>? Mn:1bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> Mmi3NlI5OTlzOU[=
231-H2N MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rIXlDjiJN{MEFCpO69\y:vTB?= MVuyOEBp NG\TPIJqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M1LhbFIzQDF7MUm2
A549  NX7BfFFyTnWwY4Tpc44hSXO|YYm= NUK3b|dvOjByL{SwNEDPxE1? MVny[ZN2dHS|IHnuJIEh\G:|ZT3y[ZNxd26|aY\lJIlv[3KnYYPlJIlvKFKRUx?= M1;ldFIzPzd|Nkm3
A549  NXnS[JpiTnWwY4Tpc44hSXO|YYm= NHG4XYQxNTRyMDFOwG0> NHzyd|EzNTR6IHi= NIDzTJdk[XW|ZYOgcY9z\SCvdFTORUB1cGGwIH7EUmEh\GGvYXfl M3;WUVIzPzd|Nkm3
A549  NFLvd4xHfW6ldHnvckBCe3OjeR?= Mn64NVAxKM7:TdMg NULpb3Z4OOLCk{S4JIg> NX;6Rmc3[2G3c3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v NWPVN3V4OjJ5N{O2PVc>
A549  MXPGeY5kfGmxbjDBd5NigQ>? NWrhVop5OTByIN88UeKh NV25SnlIOOLCk{S4JIg> NU\3cFlV[2G3c3XzJHBMTDFiY3zlZZZi\2V? NXj2WWVHOjJ5N{O2PVc>
A549  M1foZ2Z2dmO2aX;uJGF{e2G7 MojkNVAxKM7:TdMg MY[w5qCUPDhiaB?= NXzFWFJz[2G3c3XzJI1qfG:laH;u[JJq[WxibH;jZYxqgmG2aX;uJI9nKEKjeB?= MXKyNlc4OzZ7Nx?=
A549  NHHCcpZHfW6ldHnvckBCe3OjeR?= NUe2bGxlOTByIN88UeKh MWmw5qCUPDhiaB?= MYDk[YNz\WG|ZYOgUW1RKGGwZDDBWHAhdGW4ZXzz NYrCeHdFOjJ5N{O2PVc>
MCF-7/Her-18  MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnrWVMxNjR{LUG3NFAh|rypL33M NECybokzPCCq MYLpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MkjPNlI3OjF2MES=
MCF-7 MnjGVGRVN1CFSTDUdoVifG2nboS= NYS4UZZ[OC5{NTFOwIcwdWxw NF3MZ|QyNTRiaB?= NUK4cJd6e2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? M3TTcFIzPTlzMki0
MDA-MB-231 NX;z[JUzWESWL2DDTUBVemWjdH3lcpQ> MnywNE4zPSEQvHevcYwv MWCxMVQhcA>? NIPKPWx{cG:5czDzbYdvcW[rY3HueEApWMLiPDCwMlA2MSCleYTveI95cWNiZX\m[YN1 NVvQbVZpOjJ3OUGyPFQ>
MDA-MB-235  NHfBUZFRTFRxUFPJJHRz\WG2bXXueC=> NWjtcXZROC5{NTFOwIcwdWxw MkXNNU01KGh? MX7zbI94eyC|aXfubYZq[2GwdDCoVOKhRCByLkC1LUBkgXSxdH;4bYMh\W[oZXP0 Mo\0NlI2QTF{OES=
MCF-7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\KXlExNTJizsznM41tNg>? MXGyOE81QCCq NIrLU5BGSzVyPUGuNkDPxGdxbVy= M3zRXVIzPTlzMki0
NCCIT  MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXrNlDjiJNzNEFCpO69\y:vbB?= MlfLO|IhcA>? MXTMSFUxRTF{MNMg{txoN22uwrC= NY\tO4N1OjJ3NkKxOlA>
NCCIT  Mnf2SpVv[3Srb36gRZN{[Xl? M2Xpe|czKGh? NVfZOWVTe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5xsA> NY[yd2tJOjJ3NkKxOlA>
NCCIT  Ml\FSpVv[3Srb36gRZN{[Xl? MVS3NkBp NH;1eFV{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDjZZNx[XOnLUigZYN1cX[rdIpCpC=> MYWyNlU3OjF4MB?=
NCCIT  NUXFNGkxTnWwY4Tpc44hSXO|YYm= NUnVPVBqPzJiaB?= MV7zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNTliYXP0bZZqfHoEoB?= M3nuSVIzPTZ{MU[w
NCCIT  MYfGeY5kfGmxbjDBd5NigQ>? MXW3NkBp MXnzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? M2f5UlIzPTZ{MU[w
NCCIT  NUXqOFU4TnWwY4Tpc44hSXO|YYm= MUi3NkBp MVnzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgRoNtNTJiY3;ueIVvfA>? NHXWS2gzOjV4MkG2NC=>
NCCIT  MV\GeY5kfGmxbjDBd5NigQ>? M1;rWlczKGh? NEXmdGp{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhS3m2LXOgcIV3\Wx? NVjCWJBnOjJ3NkKxOlA>
HeLa M1vOUGZ2dmO2aX;uJGF{e2G7 NWrITZJKOzBxN{Cg{txoN22u Mk\BNlTDqGh? M3PRPYlv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 MmDnNlI1QDd7M{e=
MCF-7  Mnn5SpVv[3Srb36gRZN{[Xl? NYHPbmhzOzBxN{Cg{txoN22u MU[yOOKhcA>? MkjHbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKheDV|78{MRXRONHB{MdMgZY5lyqCJQVTEOFU> MVeyNlQ5Pzl|Nx?=
HeLa MXzDfZRwfG:6aXPpeJkhSXO|YYm= NI\IdZA{OC95MDFOwIcwdWx? NH3Pe|IzPMLiaB?= MYjpcoR2[2W|IHjp[4htgSC|aXfubYZq[2GwdDDs[ZZmdHNib3[g[pJi\22nboTl[EBFVkFicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21? MY[yNlQ5Pzl|Nx?=
MCF-7  MnX6R5l1d3SxeHnjbZR6KEG|c3H5 MUGzNE84OCEQvHevcYw> MoiwNlTDqGh? NHz6NoNqdmS3Y3XzJIhq\2iueTDzbYdvcW[rY3HueEBt\X[nbIOgc4Yh\nKjZ33lcpRm\CCGTlGgdoVt\WG|ZTDpcpRwKHSqZTDjfZRweGyjc32= NYflSVZGOjJ2OEe5N|c>
NT2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjrOYtmOTByLU[wNOKh|rypL33s NYjrUWc1OjRiaB?= MVjJR|UxRTRyMDFCuYcwdWx? MnLYNlI1Pjl7NUK=
NT2 MmnSSpVv[3Srb36gRZN{[Xl? NWTDW2ptPDBywrFOwIcwdWx? M{\pT|I1KGh? Ml[2d4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiY3HzdIF{\S1|LEisPUBi[3Srdnn0feKh MYGyNlQ3QTl3Mh?=
NT2 NHHkfFRHfW6ldHnvckBCe3OjeR?= NXLWTnp{PDBywrFOwIcwdWx? M2r1[lI1KGh? MX\zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NVXNV|d[OjJ2Nkm5OVI>
NT2 NYTYcHRSTnWwY4Tpc44hSXO|YYm= NYDENWZRPDBywrFOwIcwdWx? MXOyOEBp NIHIU2R{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDCZ4wuOiCuZY\lcC=> NV7CVXVLOjJ2Nkm5OVI>
CHO MmDWSpVv[3Srb36gRZN{[Xl? MXSyMlXDqM7:Zz;tcC=> Mn[2NVghcC94IHS= NWLhbGhDcW6mdXPld:KheGW{c3nzeIVv[2Vib3[gZ4hzd22xc3;t[UBl[W2jZ3W= M{HOflIzOjNyMUm1
Jurkat NF3kWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof4NE0yODEEoN88[{9udA>? M3vH[FI1KGh? MoTnZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> NYnFZWhSOjJ{MkOzN|I>
Jurkat NFnlVI1HfW6ldHnvckBCe3OjeR?= NWTzfHJyOzEEoN88[{9udA>? NYXZSGpzOjRiaB?= MkLTbY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCleXPsbY5{KER|LDDBJIFv\CCEMR?= M4HYSFIzOjJ|M{Oy
Jurkat MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCwMVExOMLizsznM41t MUKyOEBp MlPpbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJJdqfGhiYX6gTWM2OCC4YXz1[UBw\iBzMEFOwIcwdUx? MWSyNlIzOzN|Mh?=
Jurkat NYrtUYVHTnWwY4Tpc44hSXO|YYm= MlHqN|DDqM7:Zz;tcC=> NYfFVHRnOjRiaB?= NUDudIZDcW6lcnXhd4V{KHSqZTDl[oZm[3Rib3[gdJlkdmmmaX;u[UBwdiCyaH;zdIhwenmuYYTpc44hdGW4ZXzzJI9nKGirc4TvcoUhUDKDLmi= NFvGO2kzOjJ{M{OzNi=>
U2OS EGFPnls Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17ET|AuOsLizsznM41t NF\FTW8zPCCq M3;5OIlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> M2fuTVIyQDFzMEC3
U2OS KuEnls NF22[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2wMVLDqM7:Zz;tcC=> NV;zW3ZiOjRiaB?= NXrYb4Q6cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NH7BWZgzOThzMUCwOy=>
MCF-7 NWfpdJRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjsToQxNTRyMDFOwG0> MYK3NkBp NH\NdmpNSzVyPUG1NU45yqEQvF2= NI\0S3YzOTdyM{K5NS=>
MCF-7/Adr  Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrJbXIxNTRyMDFOwG0> MVG3NkBp NV6yUpF1VEN3ME21PE42yqEQvF5CpC=> NIG1fWMzOTdyM{K5NS=>
WI-38 NUXPWIY2TnWwY4Tpc44hSXO|YYm= NUL1dmRUOC92MD:4NQKBkc7:Zz;tcOKh MW[zJIg> MWnpcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg M3\4eFIyPTl7NkGy
hBMSC MX7GeY5kfGmxbjDBd5NigQ>? MVmwM|QxNzhy4pEJ{txoN22uwrC= MnXIN{Bp NF;HWIxqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MVKyNVU6QTZzMh?=
NCI-H23 Mni1SpVv[3Srb36gRZN{[Xl? NWP2UW1mOC92MD:4NQKBkc7:Zz;tcOKh NVf3bVJXOyCq M3TBTYlv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> NHeyO40zOTV7OU[xNi=>
A-549 MW\GeY5kfGmxbjDBd5NigQ>? NFXVcmgxNzRyL{iw5qCK|rypL33sxsA> MmTWN{Bp NFjPZXNqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh MWGyNVU6QTZzMh?=
PBL  MYTGeY5kfGmxbjDBd5NigQ>? M3TSV|AwPDBxOEFihKnPxGdxbX|CpC=> MkfxN{Bp Ml7ObY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NUDscWhGOjF3OUm2NVI>
pol β −/− MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTyNE4zPS1{MEFCpO69\y:vbB?= M3nwPVI1yqCq NHP5Vnhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? MX:yNVI2OTl2NB?=
pol β +/+ MkD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn74NE4zPS1{MEFCpO69\y:vbB?= NYTXeJQyOjUEoHi= NEC5XoZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4l1cCCrbnPy[YF{cW6pIHPvcoNmdnS{YYTpc45{yqB? MXWyNVI2OTl2NB?=
pol β −/− NVz4WmV6TnWwY4Tpc44hSXO|YYm= NFX3NokxNTJwNTFOwIcwdWx? MlztNkBp M3fTZ4NifXOnczDEUmEh\GGvYXfl NUPCU2Q{OjF{NUG5OFQ>
pol β +/+ MX7GeY5kfGmxbjDBd5NigQ>? M2mxSFAuOi53IN88[{9udA>? NG\qUGUzKGh? M3jGWYNifXOnczDEUmEh\GGvYXfl M3fFV|IyOjVzOUS0
pol β −/− M1m0NWZ2dmO2aX;uJGF{e2G7 M2X3WlAuPSEQvHevcYw> MYK0PEBp NXfw[4w1[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M3XtNFIyOjVzOUS0
pol β +/+ MX\GeY5kfGmxbjDBd5NigQ>? M1jzNlAuPSEQvHevcYw> NFXp[nA1QCCq Mn7ZZ4F2e2W|IH3pZ5JwdnWlbHX1d{Bld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 Mmm4NlEzPTF7NES=
TK6  Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjNZlJHOjVvMUWwJO69\y:vbB?= MWq5OkBp NXnFW4FEcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? Ml;3NlExQDF2OEe=
TK6  sLUC+Apn1 NGn4[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTaNlUuOTVyIN88[{9udA>? NFHze5E6PiCq NUKzVYhxcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MoDWNlExQDF2OEe=
TK6 sAPE1+Apn1 M1;4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjufVN7OjVvMUWwJO69\y:vbB?= M1T5O|k3KGh? Mojxd4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJIdzd3e2aDDkc5NmKGSncHXu[IVvfGy7 M{C4eVIyODhzNEi3
HCT116 NV33VWtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjvSZczPS1zNUCg{txoN22u MWe5OkBp MVPpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MXKyNVA5OTR6Nx?=
HCT116 sLUC+Apn1 M3;PV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXyVYUzPS1zNUCg{txoN22u NYT4coN5QTZiaB?= NEXoZWVqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MmTGNlExQDF2OEe=
HCT116 sAPE1+Apn1 MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1POWFI2NTF3MDFOwIcwdWx? NYr5e2YxQTZiaB?= NH\INZB{cWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= M3vYPVIyODhzNEi3

... Click to View More Cell Line Experimental Data

In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
Saline
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02166463 Recruiting Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma National Cancer Institute (NCI) March 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Childrens Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01390584 Recruiting Lymphoma Eastern Cooperative Oncology Group|National Cancer Institute (NCI) April 2012 Phase 2
NCT01132807 Active, not recruiting Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 2010 Phase 2
NCT01026220 Active, not recruiting Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Childrens Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How about the strength of Bleomycin Sulfate(S1214) in terms of Units/mg?

  • Answer:

    Our S1214 Bleomycin Sulfate is 1500 Units/mg.

  • Question 2:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID